Literature DB >> 16893754

Coronary revascularization in patients with obstructive sleep apnea syndrome.

Jay K Bhama1, Samuel Spagnolo, E P Alexander, Michael Greenberg, Gregory D Trachiotis.   

Abstract

BACKGROUND: There is a paucity of clinical information regarding therapy for ischemic heart disease (IHD) in patients with obstructive sleep apnea syndrome (OSAS). We evaluated our experience with surgical revascularization in this subset of patients.
METHODS: Between January 1998 and April 2001, 20 patients with OSAS underwent isolated coronary artery bypass grafting (CABG). Outcomes were compared to a matched control group consisting of 65 patients.
RESULTS: Patients with OSAS and the controls were similar with regard to age (65.8 years versus 65.2 years), ejection fraction (44.5% versus 46.9%), and systolic blood pressure (141 mmHg versus 142 mmHg). However, they were comparatively heavier (212 lb versus 188 lbs, P < .03), had higher pulmonary artery pressures (42 mmHg versus 34 mmHg, P < .001), higher pulmonary capillary wedge pressures (17 mmHg versus 14 mmHg, P < .01), higher left ventricular end diastolic pressures (20 mmHg versus 18 mmHg, P < .04), and a greater incidence of diabetes (55% versus 30%, P = .049). Patients with OSAS were more likely to require prolonged ventilation (40% versus 0%, P < .001) and tracheostomy (10% versus 0%, P = .01) and have a protracted intensive care unit (ICU) course (9 days versus 3 days, P = .002) and hospitalization (24 versus 13, P = .003). There were no peri-operative deaths, and both groups had significant improvement in angina and functional class. At a mean follow-up of 59 months, angina recurrence was 10% and survival was 95% in patients with OSAS.
CONCLUSION: Patients with OSAS and IHD requiring coronary revascularization have substantial risk for pulmonary morbidity that impacts the duration of hospitalization but not mortality. Good symptom control and early to mid-term survival may be achieved in this subset of patients with aggressive peri-operative management of their OSAS.

Entities:  

Mesh:

Year:  2006        PMID: 16893754     DOI: 10.1532/HSF98.20061072

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  6 in total

1.  Postoperative complications after elective coronary artery bypass grafting surgery in patients with sleep-disordered breathing.

Authors:  Maria Tafelmeier; Teresa Weizenegger; Sarah Ripfel; Miriam Fauser; Bernhard Floerchinger; Daniele Camboni; York Zausig; Sigrid Wittmann; Marzena A Drzymalski; Florian Zeman; Christof Schmid; Lars S Maier; Stefan Wagner; Michael Arzt
Journal:  Clin Res Cardiol       Date:  2018-06-12       Impact factor: 5.460

2.  Obstructive sleep apnea-induced multi-organ dysfunction after elective coronary artery bypass surgery in coronary heart disease patients.

Authors:  Jiayang Wang; Xinxin Wang; Wenyuan Yu; Kui Zhang; Yongxiang Wei
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

3.  Delirium after cardiac surgery: have we overlooked obstructive sleep apnea?

Authors:  Aibek E Mirrakhimov; Timothy Yen; Madan M Kwatra
Journal:  Med Hypotheses       Date:  2013-04-22       Impact factor: 1.538

4.  Obstructive sleep apnea and postoperative complications in patients undergoing coronary artery bypass graft surgery: a need for preventive strategies.

Authors:  Babak Amra; Nasim Niknam; Mohsen Mir Mohammad Sadeghi; Majid Rabbani; Ingo Fietze; Thomas Penzel
Journal:  Int J Prev Med       Date:  2014-11

5.  Cervical computed tomography in patients with obstructive sleep apnea: influence of head elevation on the assessment of upper airway volume.

Authors:  Fábio José Fabrício de Barros Souza; Anne Rosso Evangelista; Juliana Veiga Silva; Grégory Vinícius Périco; Kristian Madeira
Journal:  J Bras Pneumol       Date:  2016 Jan-Feb       Impact factor: 2.624

Review 6.  Association between Obstructive Sleep Apnea and Myocardial Infarction: A Systematic Review.

Authors:  Fernanda Porto; Yuri Saho Sakamoto; Cristina Salles
Journal:  Arq Bras Cardiol       Date:  2017-03-30       Impact factor: 2.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.